Please login to the form below

Not currently logged in
Email:
Password:

Horizant

This page shows the latest Horizant news and features for those working in and with pharma, biotech and healthcare.

US shortage of GSK’s restless legs syndrome treatment Horizant

US shortage of GSK’s restless legs syndrome treatment Horizant

FDA blames contract manufacturer delays. Delays at GlaxoSmithKline's (GSK) contract manufacturer have caused a shortage in the US of restless legs syndrome treatment Horizant, according to the FDA. ... Then in November 2012, GSK and XenoPort agreed to

Latest news

  • GSK sales fall for first quarter of 2011

    Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

  • GSK Restless Legs Syndrome drug approved

    GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs Syndrome. ... Horizant's approval for the condition was based on two 12-week clinical

  • FDA rejects GSK and Xenoport's Horizant

    GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics